CurveBeam AI Revises Share Placement Timeline and Minimum Subscription Terms in $2 Million Capital Raise

Details of CurveBeam AI's Share Placement and Pricing

CurveBeam AI Limited, trading on the ASX under ticker CVB and ABN 32 140 706 618, announced an updated non-pro rata offer of ordinary fully paid shares through a disclosure document. The company proposes issuing up to 111.1 million ordinary shares at AUD $0.018 each, representing an existing class of securities that will rank equally with current ordinary shares from the issue date.

The offer is structured as a Share Purchase Plan conducted under a Section 713 transaction-specific prospectus, due to the per-shareholder participation limit of AUD $100,000 exceeding the AUD $30,000 cap set by ASIC instrument 2019/547. This regulatory framework enables CurveBeam AI to offer securities to eligible shareholders while complying with Australian Securities and Investments Commission requirements and ASX Listing Rules.

Revised Offer Timeline and Application Terms

Following the initial 8 July 2026 announcement, CurveBeam AI has updated the indicative timeline for the offer. The disclosure document is scheduled for ASIC lodgement on 3 August 2026, with the prospectus and acceptance forms available to investors from 4 August 2026. The offer opens on 4 August 2026 and closes on 28 August 2026, with the intended issue date on 4 September 2026.

Shareholders on the record date are eligible to apply for shares under the Share Purchase Plan, with a minimum application value of AUD $1,000 and a maximum of AUD $100,000 per shareholder. The total offer is capped at AUD $2 million, aligning with the company's available capacity to issue shares without further shareholder approval. If demand exceeds this cap, CurveBeam AI will implement scale-back arrangements at its discretion, refunding excess application funds without interest.

Use of Capital and Strategic Market Expansion

Proceeds from the placement will be allocated to key strategic areas including sales and marketing, research and development, and supply chain improvements. A significant portion of the capital will focus on the China market launch, underscoring CurveBeam AI's strategy to expand its presence in the Asia-Pacific region. Additionally, funds will cover offer-related costs and provide working capital to support ongoing operations.

The emphasis on entering the China market highlights the company's pursuit of growth opportunities in one of the largest technology and healthcare sectors globally. This geographic diversification aims to reduce dependence on current markets and position CurveBeam AI as a regional competitor in high-growth industries. Balancing investment in R&D and supply chain enhancements reflects a focus on innovation alongside scalable operations.

Compliance with Regulatory Approvals and ASX Listing Rules

CurveBeam AI is utilising its placement capacity under ASX Listing Rule 7.1 to facilitate this offer. Of the 111.1 million shares proposed, approximately 67.7 million will be issued under the 15% placement capacity without shareholder approval, while an additional 43.4 million shares will be issued under the 10% placement capacity pursuant to Listing Rule 7.1A, applicable to eligible companies.

The company confirmed no related parties as defined by Listing Rule 10.11 are participating in the issue, ensuring no conflicts of interest or related-party transactions requiring disclosure. No external approvals beyond ASX Listing Rules are necessary for the unconditional progression of the offer. CurveBeam AI has not appointed a lead manager or broker, will not underwrite the placement, and will not pay handling fees or commissions to brokers submitting acceptances on behalf of shareholders.

Shareholder Allocation and Dividend Policy

The allocation policy prioritises existing security holders, allowing each eligible shareholder on the record date to apply for new shares up to AUD $100,000. This policy ensures equitable participation across the shareholder base without preferential treatment.

CurveBeam AI confirmed that the capital raise will not impact its dividend or distribution policy. Future dividend decisions will remain independent of this placement and depend on the company’s financial performance, cash flow, and strategic needs at the relevant time.

Company Overview and Market Positioning

CurveBeam AI Limited is an ASX-listed technology firm focused on artificial intelligence and imaging solutions. While the update does not detail the company’s operations, its capital raise priorities—R&D, sales and marketing, and supply chain—indicate activity in a competitive, innovation-driven sector. The focus on China market entry signals significant commercial opportunity and commitment to regional expansion.

The AUD $2 million capital raise reflects the company’s current development stage and funding needs. Pursuing simultaneous investment in China market entry, R&D, and supply chain improvements demonstrates an aggressive growth strategy. Investors should consider the execution risks and capital intensity associated with international market expansion.

Amendments to Previous Announcement and Investor Information

The 28 July 2026 update amends the initial 8 July 2026 announcement, revising the offer timeline and minimum subscription terms. These changes likely stem from regulatory finalisations, offer parameter adjustments, or market feedback. CurveBeam AI has maintained transparency by lodging the update with the ASX.

Investors can access the disclosure document and detailed offer terms at https://investors.curvebeamai.com/. This portal provides the prospectus, acceptance forms, and other materials necessary for informed investment decisions. The company complies with ASX continuous disclosure obligations through this formal update.

Participation Requirements and Investment Thresholds

Eligible shareholders may participate with a minimum application of AUD $1,000 and a maximum of AUD $100,000, balancing administrative efficiency with accessibility. The AUD $2 million cap aligns with the company’s issuance capacity under ASX Listing Rules, preserving flexibility for future capital raises. Scale-back provisions allow fair allocation if applications exceed available shares, with refunds processed without interest.

Strategic Timing and Market Launch Execution

The capital raise closing on 28 August 2026 and share issue on 4 September 2026 enable timely deployment of funds into strategic priorities. The focus on the China market launch indicates a major growth initiative requiring regulatory compliance, marketing investment, and operational planning.

The revised terms following the July announcement suggest refined market entry strategies and capital needs. Investors should monitor future updates for progress on China expansion and effectiveness of capital deployment across sales and marketing, R&D, and supply chain development.